Navigation Links
Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008

NEW YORK, Nov. 1 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation (MJFF) for Parkinson's Research today announced the launch of its 2008 Target Validation effort. Under this annual program the Foundation will award up to $2 million in 2008 for projects designed to validate the therapeutic potential of scientific discoveries, pushing them one step closer to possible pharmaceutical industry investment and clinical trials.

"Target Validation is emblematic of our Foundation's aggressive, 'get-it done' approach to driving PD drug development and speeding delivery of treatments that can improve patients' quality of life," said Katie Hood, interim chief executive officer of MJFF. "Target Validation has a single purpose: to definitively assess the importance of promising targets by proving or disproving their druggability. This is a vital component of the Foundation's strategy to accelerate the pace of drug development by reducing industry's risk around investing in potential PD treatments."

Target Validation 2008 specifically seeks investigator-initiated applications to demonstrate that modulation of a specific cellular target (such as a gene or protein) results in a PD-relevant therapeutic response in an appropriate whole-animal mammalian model of PD. Of particular interest are targets whose manipulation holds the potential to treat the symptoms of PD, including both 'motor' and 'non-motor' symptoms such as cognitive dysfunction, autonomic dysfunction, sleep disorders and depression. Also of interest are targets that could be used to protect or restore degenerating neurons, as well as those that can treat complications of current PD treatments (e.g., dyskinesias).

This year, for the first time, MJFF has identified several Contract Research Organizations (CROs) to help applicants gather critical information essential for ensuring studies are appropriately designed to validate or invalidate targets, such as dosing amounts and brain bioavailability. Grant submissions must include the necessary pharmacokinetic and toxicology studies required to fully validate their targets, and the Request for Applications (RFA) includes a list of CROs equipped to perform these studies. For investigators who are not able to carry out the required test in their own labs, MJFF has identified several Contract Research Organizations (CROs) to help applicants gather this critical information. The expertise and resources provided by the CROs will allow awardees to obtain information critical to fully validating the proposed targets.

Target Validation pre-proposals are due by December 18, 2007 and funding is anticipated by spring 2008.

A conference call with MJFF Research Programs staff to further clarify the aims and goals of this initiative will be held November 27 at 12 p.m. U.S. Eastern Time. Researchers wishing to participate in the call must RSVP to and will receive an e-mail reply with call-in details.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. The Foundation has funded over $95 million in research to date, either directly or through partnerships.

SOURCE Michael J. Fox Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Gest Says Will Reveal Damning Secrets On Michael Jackson
2. Ask Right Questions and Save Country from Further Healthcare Crisis: Michael Moore
3. Michael J. Fox Foundation Awards $710,000 to Understanding of Parkinsons Disease Subtypes
4. Where is Our Soul, Asks Michael Moore
5. Michael Moores Sicko Freely Available on the Internet
6. Woodruff Foundation Grant To Support Doctorate Of Nursing Practice Program
7. Kalam To Lay Foundation Of Vellore Research Center
8. Nippon Foundation To Help Leprosy Patients
9. Parents Launch SV40 Cancer Foundation In Memory of Son
10. Cancer Aid And Research Foundation: Offering Endless Hope To Cancer Patients
11. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: